Literature DB >> 24519640

Diaphragmatic hernia after lung percutaneous radiofrequency ablation: incidence and risk factors.

Nicolas Alberti1, Gilbert Ferretti, Xavier Buy, Marie Desjardin, Sultan Al Ammari, Roberto-Luigi Cazzato, Valérie Monnin-Bares, Dominique Bechade, Gregoire Desolneux, Audrey Michot, Jean Palussiere.   

Abstract

PURPOSE: To evaluate diaphragmatic hernias (DH) after percutaneous radiofrequency ablation (PRFA) for basal lung nodules and to detect risk factors.
MATERIALS AND METHODS: Between January 2009 and December 2012, the presence of DH was retrospectively recorded in all of the patients who underwent PRFA with multitine expandable electrodes for ablation of nodules in the lower lobe. All nodules were classified into three groups according to the location of the tines after deployment relative to the diaphragm: In group 1, the tines were at a distance of >1 cm from the diaphragm; in group 2, at least one tine was in contact with the diaphragm without perforation; and in group 3, at least one tine was perforating the diaphragm.
RESULTS: We recorded 4 cases of DH (3 on the left side, 1 on the right side) in 156 patients (2.3% of procedures). The delay of onset was 7.8 months. DH occurred in groups 2 (n = 1) and 3 (n = 3). Only the 3 cases that occurred on the left side were symptomatic (2 intussusceptions and 1 gastroesophageal reflux) and were surgically repaired. The electrode was positioned in the center of the diaphragm in all cases.
CONCLUSION: The central position of the electrode and the contact of at least one tine with the diaphragm after deployment seem to be a risk factor to develop DH.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24519640     DOI: 10.1007/s00270-014-0854-9

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  1 in total

1.  Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience.

Authors:  Alexis Gonnet; Laura Salabert; Guilhem Roubaud; Vittorio Catena; Véronique Brouste; Xavier Buy; Marine Gross Goupil; Alain Ravaud; Jean Palussière
Journal:  BMC Cancer       Date:  2019-12-03       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.